RESUMO
BACKGROUND: Potassium citrate (K-Cit) is one of the therapeutic solutions broadly used in patients with urolithiasis. However, recent studies have shown that it is not so effective. Therefore, the goal of our study was to evaluate the effect of a combination of K-Cit - MgCl2 oral supplements, on urinary stone size. MATERIALS AND METHODS: This study was performed on 70 asymptomatic urolithiasis cases. The supplements included K-Cit and magnesium chloride (MgCl2), purchased from (Merck Company, Germany). The patients were randomly divided into two groups. The urinary stone size was measured in the control group after prescribing K-Cit alone and the treated group with combination of K-Cit and MgCl2 for 4 weeks by ultrasonography and also urinary parameter was measured in each groups. RESULTS: The mean age of patients was 16.26 ± 5.70 years. Hyperoxaluria and hypercalciuria were seen in 70% and 52% of patients, respectively. Initially, the mean urinary stone size was measured in each groups and there is not any significant different. However, we find a significant decrease in urinary stone size in group which is treated with combination of K-Cit and MgCl2 for 4 weeks in comparison with control group treated with K-Cit alone in the same duration of therapeutic course (5.1 ± 0.8 vs. 2.5 ± 1.2, P < 0.05). All ultrasonography were performed by one radiologist and device. CONCLUSION: Our results suggested that a combination of K-Cit and MgCl2 chloride is more effective on decreasing urinary stone size than K-Cit alone.
RESUMO
BACKGROUND: Potassium citrate (K-Cit) is one of the medications widely used in patients with urolithiasis. However, in some cases with calcium oxalate (CaOx) urolithiasis, the significant response to alkaline therapy with K-Cit alone does not occur. There is scarce published data on the effect of magnesium chloride (Mg-Cl(2)) on urolithiasis in pediatric patients. This study aimed to evaluate the effect of a combination of K-Cit - MgCl(2) as oral supplements on urinary parameters in children with CaOx urolithiasis. METHODS: This study was conducted on 24 children with CaOx urolithiasis supplements included potassium citrate (K-Cit) and magnesium chloride (Mg-Cl(2)). The serum and urinary electrolytes were measured before (phase 0) and after prescribing K-Cit alone (phase 1) and a combination of K-Cit and Mg-Cl(2) (phase 2). Each phase of therapy lasted for 4 weeks. RESULTS: The mean age of patients was 6.46 ± 2.7 years. Hyperoxaluria and hypercalciuria were seen in 66% and 41% of patients, respectively. Serum magnesium increased significantly during phase 2 comparing with phase 0. Urinary citrate level was significantly higher in phase 1 and 2 in comparison with phase 0, P < 0.05. In addition, urinary oxalate excretion was significantly diminished in phase 2 comparing with phase 0 and 1, P < 0.05. Soft stool was reported by 4 patients, but not severe enough to discontinue medications. CONCLUSIONS: These results suggested that a combination of K-Cit and Mg-Cl(2) chloride is more effective on decreasing urinary oxalate excretion than K-Cit alone. The Iranian Clinical Trial registration number IRCT138707091282N1.
